A Randomized Double-blind Placebo-controlled Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localized High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02) (D9727C00001)
Learn More About This Study
